HOME >> BIOLOGY >> NEWS
Treatment With IL-2 Plus HAART Markedly Reduces HIV In Immune System "Hiding Places"

Individuals treated with interleukin-2 (IL-2) plus highly active antiretroviral therapy (HAART) have significantly fewer resting CD4+ T cells in their bloodstream which harbor HIV than patients receiving HAART alone, according to a study of 26 patients conducted at the National Institute of Allergy and Infectious Diseases (NIAID). Resting CD4+ T cells are among the "safe havens" where HIV may persist for years - sewn into the cells' genes - despite aggressive three-drug antiretroviral therapy.

In resting CD4+ T cells taken from the bloodstream ("peripheral blood") of a small number of study patients receiving IL-2 plus HAART, the researchers have been unable to find HIV capable of replicating, even when they have looked for the virus in millions of cells with sensitive laboratory procedures.

Anthony S. Fauci, M.D., NIAID director and chief of the NIAID Laboratory of Immunoregulation (LIR), plans to present these new findings at the 36th Annual Meeting of the Infectious Diseases Society of America in Denver, Colo., on Sunday, November 15 at 8:30 a.m. Mountain Time. The lead LIR scientist on the new studies is Tae-Wook Chun, Ph.D., who, with Dr. Fauci and other colleagues, has published several seminal papers on latent reservoirs of HIV.

The NIAID team studied two different groups of HIV-infected patients, 12 receiving HAART (generally a combination of at least three antiretroviral drugs including a protease inhibitor) and 14 receiving HAART plus IL-2, administered either intravenously or subcutaneously. IL-2 is a regulatory protein of the immune system produced in the body by T cells. IL-2 has potent effects on the proliferation, differentiation and activity of a number of immune system cells, notably T cells. The 14 patients on HAART plus IL-2 received doses of IL-2 totaling 3 to 18 million international units per day during five-day treatment cycles, followed by a rest period of at least eight weeks before the next treatment cycle.

At the
'"/>

Contact: Greg Folkers
gfolkers@nih.gov
301-496-2263
NIH/National Institute of Allergy and Infectious Diseases
15-Nov-1998


Page: 1 2 3

Related biology news :

1. St. Petersburg/New Haven Partnership for HIV/AIDS Care, Treatment and Support launched
2. Treatment stimulates growth and regeneration of injured adult skeletal muscle
3. Treatment of lupus in mice may point the way to human treatment
4. Treatment in mice proves effective against Duchenne muscular dystrophy
5. Treatment protects mouse ovaries from radiation therapy
6. National Institute on Drug Abuse launches National Drug Addiction Treatment Clinical Trials Network
7. Treatment restores normal heart rhythm in patients
8. Researchers Develop New Treatment For Hepatitis B And C As Nation Anticipates Surge In Number Of Cases
9. Researchers: Exciting Discovery Might Improve Cancer Treatment
10. Coffee Without Addiction, Possible New Treatment For Osteoporosis, Wrinkle-Free Cotton, And More
11. Scientists Discover Molecular Trigger Of Mucus Production, Suggesting First Treatment For Deadly Bronchitis, Other Diseases

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/15/2016)... Md. , Nov. 15, 2016  Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...
(Date:11/14/2016)... Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), ... in challenging operating environments, announced its results for the ... a conference call to discuss these results on November ... Key Recent Accomplishments ... acquire Vislink Communication Systems. The purchase is expected to ...
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 01, 2016 ... ... the US Computational Science Symposium (CSS) and the popularity of US Single Day ... will take place in early Summer 2018, in Raleigh, NC. Topics of the ...
(Date:12/2/2016)... MA (PRWEB) , ... December 02, 2016 , ... Robots ... Light Event on December 3rd, 2016. The event, which is held on the ... work with helping Americans with Disabilities back into the workplace. Suitable Technologies is partnering ...
(Date:11/30/2016)... CLEVELAND , Nov. 30, 2016  GenomOncology today announced ... Vice President of Medical Affairs.  Dr. Coleman ... enhancing the company,s proprietary knowledge-enabled platform. The GenomOncology software suite ... of genetic sequencing data and clinical decision support, from quality ... , ...
(Date:11/30/2016)... 30, 2016 /PRNewswire/ -  Equicare Health Inc ., the ... recognized as one of the top 100 companies in ... listing that distinguishes the top digital health companies across ... step forward this year continually upgrading our product with ... base and team," says Len Grenier , CEO ...
Breaking Biology Technology:
Cached News: